OSLO, Norway--(BUSINESS WIRE)--DiaGenic ASA (OSO:DIAG) and SRL Ranbaxy Ltd. today announced that they have signed a commercial agreement to commence marketing DiaGenic’s breast cancer test in India. This development follows rapidly from a presentation at The Federation of Obstetrics and Gynecology Societies of India (FOGSI) annual meeting in New Delhi in February where the interim results of a large Indian clinical study on this test were presented.
